Back to Atlas
CTransientStandard research/education caution
CMP-0782
Research chemical/reference listing
Insulin degludec
General biohacking / research
Bioactive effect candidate for Atlas review
Reading this compound Reference only
Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- Bioactive compound
- Primary mechanism
- Mechanism requires verification
- Primary market use
- General biohacking / research
Pharmacology
- Oral bioavailability
- Route-dependent / verify
- Half-life
- ~1–7 days (half-life-extended peptide class estimate)
- Route tags
- SubQ; Injectable; route-dependent
- Evidence level
- MCE product listing / research chemical signal
- Clinical status
- Research chemical/reference listing
- Value-for-money score
- 5 / 10
Reported protocol signal
No popular protocol verified yet; keep as reference compound until protocol signal is added.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Notes
Insulin degludec is an ultra-long-acting form of insulin used for the research of hyperglycemia caused by type 1 and type 2 dabetes. Insulin degludec shows binding efficiency with an IC 50 value of 19.59 nM for insulin receptor . Insulin degludec can be used for the research of type 1 and type 2 diabetes.